Conrad Jacobs

2.1k total citations
8 papers, 127 citations indexed

About

Conrad Jacobs is a scholar working on Oncology, Surgery and Immunology. According to data from OpenAlex, Conrad Jacobs has authored 8 papers receiving a total of 127 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 2 papers in Surgery and 2 papers in Immunology. Recurrent topics in Conrad Jacobs's work include CAR-T cell therapy research (3 papers), Cancer Immunotherapy and Biomarkers (3 papers) and Cancer therapeutics and mechanisms (1 paper). Conrad Jacobs is often cited by papers focused on CAR-T cell therapy research (3 papers), Cancer Immunotherapy and Biomarkers (3 papers) and Cancer therapeutics and mechanisms (1 paper). Conrad Jacobs collaborates with scholars based in United States, South Africa and Spain. Conrad Jacobs's co-authors include J. C. Yao, Robert A. Wolff, Alexandria T. Phan, Jaffer A. Ajani, Rachna T. Shroff, Elliot Chartash, Lokesh Jain, Bernardo L. Rapoport, Mallika Lala and Paul Ruff and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Conrad Jacobs

7 papers receiving 120 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Conrad Jacobs United States	6	89	53	40	32	20	8	127
Pooja Navale United States	8	73 0.8×	21 0.4×	16 0.4×	58 1.8×	37 1.9×	26	160
Graziana Gallo Italy	6	45 0.5×	18 0.3×	11 0.3×	44 1.4×	65 3.3×	23	158
Sergio Fava Italy	5	75 0.8×	77 1.5×	37 0.9×	8 0.3×	33 1.6×	10	165
Mansoor Noorani United States	6	45 0.5×	73 1.4×	31 0.8×	18 0.6×	18 0.9×	17	113
Iván Murrieta-Álvarez Mexico	8	36 0.4×	72 1.4×	16 0.4×	15 0.5×	18 0.9×	33	166
Jun Amaki Japan	6	98 1.1×	64 1.2×	19 0.5×	12 0.4×	12 0.6×	19	154
Virginia Mancini Italy	9	76 0.9×	62 1.2×	11 0.3×	29 0.9×	17 0.8×	30	203
Ken-Wing Lee United States	2	100 1.1×	45 0.8×	9 0.2×	116 3.6×	12 0.6×	2	142
E. Puzenat France	7	31 0.3×	74 1.4×	44 1.1×	99 3.1×	13 0.7×	19	187
Martin Salzmann Germany	8	113 1.3×	11 0.2×	41 1.0×	12 0.4×	27 1.4×	19	217

Countries citing papers authored by Conrad Jacobs

Since Specialization

Citations

This map shows the geographic impact of Conrad Jacobs's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Conrad Jacobs with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Conrad Jacobs more than expected).

Fields of papers citing papers by Conrad Jacobs

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Conrad Jacobs. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Conrad Jacobs. The network helps show where Conrad Jacobs may publish in the future.

Co-authorship network of co-authors of Conrad Jacobs

This figure shows the co-authorship network connecting the top 25 collaborators of Conrad Jacobs. A scholar is included among the top collaborators of Conrad Jacobs based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Conrad Jacobs. Conrad Jacobs is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

Cohen, Graham, Bernardo L. Rapoport, Paul Ruff, et al.. (2024). Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study. PLoS ONE. 19(11). e0309778–e0309778.

2.

Jacobs, Conrad, Bernardo L. Rapoport, Graham Cohen, et al.. (2021). Abstract CT143: Pembrolizumab bioavailability after subcutaneous administration: analysis from the KEYNOTE-555 Cohort A in metastatic melanoma. Cancer Research. 81(13_Supplement). CT143–CT143. 8 indexed citations

3.

Jacobs, Conrad, Bernardo L. Rapoport, Paul Ruff, et al.. (2021). KEYNOTE-555 Cohort B: Efficacy, safety, and PK of pembrolizumab (pembro) 400 mg every 6 weeks (Q6W) as 1L therapy for advanced melanoma.. Journal of Clinical Oncology. 39(15_suppl). 9541–9541. 11 indexed citations

4.

Ibe, Chibuike, et al.. (2013). Prevalence and Antibiotic Susceptibility Patterns of Methicillin-Resistant Staphylococcus Aureus (MRSA) Isolated from Healthy Inhabitants of Uturu Rural Communities, Abia State, Nigeria. VNU Journal of Science: Natural Sciences and Technology (Vietnam National University). 3(10). 85–91. 4 indexed citations

5.

Shroff, Rachna T., Conrad Jacobs, Robert A. Wolff, et al.. (2008). A phase II study of irinotecan and cisplatin for metastatic or unresectable high grade neuroendocrine carcinoma. Journal of Clinical Oncology. 26(15_suppl). 15550–15550. 18 indexed citations

6.

Ruff, Paul, Bernardo L. Rapoport, Stephen Falk, et al.. (2004). Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer. BMC Cancer. 4(1). 36–36. 8 indexed citations

7.

Jacobs, Conrad, et al.. (1999). Lymphomas of the head and neck.. PubMed. 26(3). 338–45. 62 indexed citations

8.

Jacobs, Conrad. (1982). Use of methotrexate and 5-FU for recurrent head and neck cancer.. PubMed. 66(11). 1925–8. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact